Sponsors

Lead Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Rockefeller University
Flinders Medical Centre
University of Southern California
Gen-Probe, Incorporated
Genentech, Inc.
General Electric
Purdue University
Biocept, Inc.
Duke University
Ikonysis
Array Genomics
Cold Spring Harbor Laboratory
Nodality
Epic Sciences
Rutgers Cancer Institute of New Jersey
Dana-Farber Cancer Institute
Johns Hopkins University
M.D. Anderson Cancer Center
Oregon Health and Science University
University of California, San Francisco
University of Chicago
University of Michigan
University of Washington
University of Wisconsin, Madison
Fred Hutchinson Cancer Center
Broad Institute of MIT and Harvard
Weill Medical College of Cornell University
Institute of Cancer Research, United Kingdom
Vitatex Inc.
Serametrix Corporation
Promega Corporation
Creatv Microtech, Inc.
Viatar LLC
Massachusetts Institute of Technology
Advanced Cell Diagnostics
ApoCell, Inc.
Beckman Coulter GmbH
Bioview, Inc.
Clearbridge BioMedics Pte Ltd., Singapore
Cynvenio Biosystems
Exosome Diagnostics, Inc.
Fluxion Biosciences
Foundation Medicine
Universitätsklinikum Hamburg-Eppendorf
Brooklyn ImmunoTherapeutics, LLC
Ohio State University
Palo Alto Research Center
Rarecells
Silicon Biosystems
The Scripps Research Institute
University of Minnesota
Janssen Diagnostics, LLC
University of Regensburg
Innocrin Pharmaceuticals Inc.

Related studies

RECRUITINGPhase 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

RECRUITINGPhase 1/2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986 · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

RECRUITINGNA

CARE Tool Study Aim 3

NCT07296887 · Gynecologic Cancer, Prostate Cancer, and more

RECRUITINGNA

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

NCT06202248 · Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer

View all related studies →

Molecular Studies and Clinical Correlations in Human Prostatic Disease

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

CARE Tool Study Aim 3

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

Trial snapshot

Condition

Locations shown

For caregivers